Last reviewed · How we verify
NCT05620251
Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
trial testing Blood test in type1diabetes in 121 participants. Completed in 12 June 2022.
28 February 2022
Quick facts
| Lead sponsor | Istanbul Medeniyet University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 3 September 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 12 June 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Blood test — full drug profile →
Conditions studied
- type1diabetes — all drugs for type1diabetes →
Sponsor
Istanbul Medeniyet University
Who can join
Adults 12 to 18, any sex, with type1diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adolescents with type 1 diabetes may be at increased risk for severe coronavirus disease-2019 (COVID-19) and are therefore prioritized for access to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. The pivotal trial that assessed the efficacy of the BNT162b2 vaccine among adolescents demonstrated 100% protection against SARS-CoV-2 infection after a two-dose regimen. However, the research did not include adolescents with type 1 diabetes. In this study, the investigators aimed to assess the humoral immune response of infection-naive adolescents with type 1 diabetes following vaccination with the BNT162b2 vaccine in comparison to that of infection-naive healthy controls and the factors associated with that response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05620251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood test
Trials testing the same drug.
- NCT06863974 — High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Im · NA · recruiting
- NCT07078435 — Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis · NA · not yet recruiting
- NCT05370300 — SNAPS Breast Cancer Patient Study Breast Cancer Patients · not yet recruiting
- NCT06820450 — Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis · not yet recruiting
- NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting
Other recruiting trials for type1diabetes
Currently open trials in the same condition.
- NCT06315127 — The CanDo (Canadian Donor Milk) Trial · NA · active not recruiting
- NCT05756829 — Type 1 Diabetes Virtual Self-management Education and Support · NA · recruiting
- NCT05421715 — Remote Digital Care Effects in Adolescents With Type 1 Diabetes · NA · recruiting
- NCT05454176 — Diabetes in African Youth · Phase 4 · recruiting
- NCT04593888 — Gluten Reduction and Risk of Celiac Disease · NA · active not recruiting
Other Istanbul Medeniyet University trials
Trials by the same sponsor.
- NCT07478380 — Transcutaneous pO₂ Monitoring in PICU · recruiting
- NCT07368244 — Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Co · recruiting
- NCT07179731 — Comparison of the Effects of External Oblique Intercostal Plane Block, Subcostal Transverse Abdominis Plane Block, and T · NA · not yet recruiting
- NCT07241455 — Validity of the Children's Chelsea Critical Care Physical Assessment Tool (cCPAx-TR) in Turkish Pediatric Intensive Care · completed
- NCT07426497 — Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05620251 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Medeniyet University
- Last refreshed: 17 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05620251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing